Long-term safety monitoring for Palynziq in PKU
Treatments studied
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study tracks the long-term safety of Palynziq (pegvaliase) in people with PKU as they take the medicine over time. It may help you and other patients understand long-term side effects and whether Palynziq stays safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of PKU based on your local medical standard.
- You are currently taking Palynziq (pegvaliase) or will start within 30 days after joining.
- You (or your legally authorized representative) can sign a consent form after the study is explained.
- You are not able to join if you are currently in another medicine/device/procedure study.
- You have not already been enrolled in this same PALace study before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This long-term study checks how the immune system reacts to Palynziq (a treatment for PKU) over time. It involves extra blood tests for people already in another PKU study called 165-501.
This trial tests an experimental medication taken as a pill to see if it can help people with PKU manage their condition. The study will check if the pill is safe and how it affects blood phenylalanine levels.
This study tests a new injection called PL54 to see if it is safe and tolerable for adults with phenylketonuria (PKU), a condition where the body cannot break down an amino acid called phenylalanine. It is designed for people with high blood phenylalanine levels and may offer a new treatment option.
This study tests a new medicine called JNT-517 for people with phenylketonuria (PKU) over a long period. It aims to see if the drug can help manage PKU safely and effectively.
This study is testing whether a new microtablet form of protein substitute is easy and acceptable for people with PKU to take. If you qualify, you'll take these tablets instead of your current protein substitute and share your experience with the research team.
This study tests a new one-time gene therapy injection (called GS1168) for adults with phenylketonuria (PKU). It aims to help your body break down the amino acid phenylalanine better, so your diet may become less strict.
Hear when a new Phenylketonuria (PKU) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.